Compile Data Set for Download or QSAR
Report error Found 41 Enz. Inhib. hit(s) with all data for entry = 2024
TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285840(US10081601, Example 22 | (6R,7R,8S)-8-(but-1-yn-1-...)
Affinity DataIC50: 2.40nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285845(US10081601, Example 27 | (6R,7R,8S)-8-(4-fluorobut...)
Affinity DataIC50: 2.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285819(US10081601, Example 1 | (6R,7R,8S)-8-methyl-4-azas...)
Affinity DataIC50: 3.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285821(US10081601, Example 3 | (6R,7R,8S)-8-(fluoromethyl...)
Affinity DataIC50: 6.20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285830(US10081601, Example 12 | (6R,7R,8S)-8-ethyl-4-azas...)
Affinity DataIC50: 6.30nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285822(US10081601, Example 4 | (6R,7R,8S)-8-(difluorometh...)
Affinity DataIC50: 6.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285841(US10081601, Example 23 | (6R,7R,8S)-8-(pent-1-yn-1...)
Affinity DataIC50: 6.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285834(US10081601, Example 16 | (6R,7R,8S)-8-vinyl-4-azas...)
Affinity DataIC50: 6.80nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285823(US10081601, Example 5 | (6R,7R,8S)-8-(chloromethyl...)
Affinity DataIC50: 7.40nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285824(US10081601, Example 6 | (6R,7R,8R)-8-(methoxymethy...)
Affinity DataIC50: 7.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50182801(CHEMBL206468 | AFEGOSTAT TARTRATE | D-Isofagomine ...)
Affinity DataIC50: 8.20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285839(US10081601, Example 21 | (6R,7R,8S)-8-(prop-1-yn-1...)
Affinity DataIC50: 9.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285846(US10081601, Example 28 | (6R,7R,8S)-8-(4,4-difluor...)
Affinity DataIC50: 11nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285820(US10081601, Example 2 | (6R,7R,8R)-8-(hydroxymethy...)
Affinity DataIC50: 13nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285838(US10081601, Example 20 | (6R,7R,8S)-8-ethynyl-4-az...)
Affinity DataIC50: 13nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285831(US10081601, Example 13 | (6R,7R,8S)-8-propyl-4-aza...)
Affinity DataIC50: 15nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285843(US10081601, Example 25 | (6R,7R,8S)-8-(3-fluoropro...)
Affinity DataIC50: 16nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285842(US10081601, Example 24 | (6R,7R,8S)-8-(3-hydroxypr...)
Affinity DataIC50: 17nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285836(US10081601, Example 18 | (6R,7R,8S)-8-((E)-2-fluor...)
Affinity DataIC50: 20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285844(US10081601, Example 26 | (6R,7R,8S)-8-(3,3-difluor...)
Affinity DataIC50: 22nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285832(US10081601, Example 14 | (6R,7R,8S)-8-(2-fluoroeth...)
Affinity DataIC50: 27nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285825(US10081601, Example 7 | (6R,7S,8S)-8-methoxy-4-aza...)
Affinity DataIC50: 32nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285835(US10081601, Example 17 | (6R,7R,8S)-8-((Z)-2-fluor...)
Affinity DataIC50: 36nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM350905((6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]oc...)
Affinity DataIC50: 56nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285826(US10081601, Example 8 | (6R,7R,8R)-6,7-dihydroxy-4...)
Affinity DataIC50: 75nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285837(US10081601, Example 19 | (6R,7R,8S)-8-(2,2-difluor...)
Affinity DataIC50: 75nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285818(US10081601, Example 1.3 | US9796680, Example Table...)
Affinity DataIC50: 222nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285828(US10081601, Example 10 | (6R,7R,8S)-6,7-dihydroxy-...)
Affinity DataIC50: 264nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285829(US10081601, Example 11 | (6R,7R,8S)-N-cyclopropyl-...)
Affinity DataIC50: 462nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285827(US10081601, Example 9 | (6R,7R,8S)-6,7-dihydroxy-4...)
Affinity DataIC50: 507nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50182801(CHEMBL206468 | AFEGOSTAT TARTRATE | D-Isofagomine ...)
Affinity DataKi:  1.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285821(US10081601, Example 3 | (6R,7R,8S)-8-(fluoromethyl...)
Affinity DataKi:  2.10nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285819(US10081601, Example 1 | (6R,7R,8S)-8-methyl-4-azas...)
Affinity DataKi:  2.60nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285839(US10081601, Example 21 | (6R,7R,8S)-8-(prop-1-yn-1...)
Affinity DataKi:  6.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285820(US10081601, Example 2 | (6R,7R,8R)-8-(hydroxymethy...)
Affinity DataKi:  7nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285834(US10081601, Example 16 | (6R,7R,8S)-8-vinyl-4-azas...)
Affinity DataKi:  7.60nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285838(US10081601, Example 20 | (6R,7R,8S)-8-ethynyl-4-az...)
Affinity DataKi:  7.90nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285822(US10081601, Example 4 | (6R,7R,8S)-8-(difluorometh...)
Affinity DataKi:  8nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285843(US10081601, Example 25 | (6R,7R,8S)-8-(3-fluoropro...)
Affinity DataKi:  15nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285844(US10081601, Example 26 | (6R,7R,8S)-8-(3,3-difluor...)
Affinity DataKi:  17nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetLysosomal acid glucosylceramidase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM285817(US10081601, Example 1.2 | US9796680, Example Table...)
Affinity DataKi:  1.40E+3nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent